Oil-in-water method for making polymeric implants containing a hypotensive lipid

Abstract

Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

We claim: 
     
         1 . A method of reducing intraocular pressure in an eye of a patient comprising administration of a population of microparticles comprising a polymeric component encapsulating travoprost in the form of oil-in-water emulsified microparticles into the anterior chamber of the eye of the patient. 
     
     
         2 . The method of  claim 1 , wherein the polymeric component comprises a poly (lactide-co-glycolide) copolymer. 
     
     
         3 . The method of  claim 1  which is terminally sterilized. 
     
     
         4 . The method of  claim 3 , wherein at least 80% of the travoprost remains stable after the sterilization. 
     
     
         5 . The method of  claim 1  having a mean particle diameter from about 30 μm to about 50 μm. 
     
     
         6 . The method of  claim 1 , wherein the maximum particle diameter is less than about 200 μm. 
     
     
         7 . The method of  claim 1 , wherein the microparticles have a release rate of the travoprost of about 0.7% per day in vitro. 
     
     
         8 . The method of  claim 1 , wherein the travoprost comprises about 10% wt/wt of the microparticles. 
     
     
         9 . The method of  claim 1 , wherein the travoprost comprises about 5% wt/wt of the microparticles.